Actively Recruiting
Impact of External Drainage of the Main Pancreatic Duct and Common Bile Duct on Pancreatic Fistula Following Pancreaticoduodenectomy
Led by Shanghai Zhongshan Hospital · Updated on 2025-01-22
322
Participants Needed
1
Research Sites
140 weeks
Total Duration
On this page
Sponsors
S
Shanghai Zhongshan Hospital
Lead Sponsor
H
Huadong Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Pancreaticoduodenectomy (PD) is the standard treatment for tumors of the pancreatic head, distal bile duct, duodenum, and ampulla of Vater. With advances in surgical experience and instrumentation, the mortality rate of PD has decreased to below 5% in high-volume pancreatic centers. However, the postoperative complication rate remains high at 25%-50%, limiting the development and application of PD. The main postoperative complications of PD are postoperative pancreatic fistula (POPF), delayed gastric emptying (DGE), post-pancreatectomy hemorrhage (PPH), and biliary leakage (BL). POPF, BL, and the subsequent abdominal infection, PPH, etc. are the main causes of death during hospitalization. Even in large, relatively mature pancreatic centers, the incidence of POPF remains as high as 10%-40%. In recent years, various methods have been used to prevent and treat POPF and BL after PD, such as pancreatic duct stent external drainage and external biliary drainage. To date, there have been many studies by domestic and foreign scholars on the advantages and disadvantages of biliary and pancreatic duct external drainage versus internal drainage in PD in terms of perioperative POPF incidence, mortality rate, etc., but the research results are not consistent. Overall, pancreatic duct stent external drainage is only recommended for patients with a high risk of pancreatic fistula during PD. Currently, there have been a few relevant studies exploring and verifying the preventive effect of pancreatic duct stent external drainage on pancreatic fistula in patients with high risk of pancreatic fistula. For example, a retrospective study of 98 patients with soft pancreatic parenchyma by Teruyuki Usub et al. found that there was no significant difference between groups with and without pancreatic duct stent in preventing pancreatic fistula. However, due to the low level of evidence, only a few risk factors such as pancreatic texture and pancreatic duct diameter were included, and the risk of POPF was not systematically evaluated. Further clinical exploration and verification are needed. In 2013, Mark P Callery et al. proposed a pancreatic fistula risk score (The fistula risk score, FRS) based on the pancreatic fistula standard defined by the International Pancreatic Fistula Study Group, which included pancreatic texture, pathological type, pancreatic duct diameter, and intraoperative blood loss. This model can be used to systematically and quantitatively evaluate the risk of POPF. Previous studies did not have a clear stratification for patients undergoing pancreatic duct stent external drainage, which may have included too many patients with a low risk of pancreatic fistula, resulting in inaccurate results. Therefore, it is necessary to re-evaluate the effectiveness of pancreatic duct stent external drainage in preventing clinically relevant pancreatic fistula based on stratification of pancreatic fistula risk and disease type. At the same time, pancreatic juice contains a variety of digestive enzymes, of which pancreatic lipase, trypsin, and chymotrypsin all need to be activated by bile to play a role in digesting and decomposing fat and protein. Theoretically, biliary and pancreatic juice diversion may be able to reduce the incidence of pancreatic fistula and its related complications in PD patients. Thus, the investigators design the present study to evaluate the impact of main pancreatic duct and biliary duct external drainage on postoperative complication, especially POPF.
CONDITIONS
Official Title
Impact of External Drainage of the Main Pancreatic Duct and Common Bile Duct on Pancreatic Fistula Following Pancreaticoduodenectomy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent before treatment
- Age 18 years or older and 80 years or younger
- ECOG performance status of 0 or 1, life expectancy of 12 weeks or more, and ASA score 2 or less
- Clinical diagnosis indicating need for pancreaticoduodenectomy for tumors of the pancreatic head, ampulla of Vater, duodenum, or distal common bile duct
- No serious dysfunction of blood, heart, lung, or autoimmune systems
- White blood cell count at least 3 x 10^9/L; absolute neutrophil count at least 1.5 x 10^9/L; platelets at least 100 x 10^9/L; hemoglobin at least 90 g/L
- Liver enzymes (AST/ALT) no more than 2.5 times the upper normal limit; total bilirubin within normal limits; creatinine no more than 1.5 times upper normal limit
- Prothrombin time and INR no more than 1.5 times upper normal limit
- Able to follow study visit plans and protocol requirements
- Intermediate or high risk of postoperative pancreatic fistula according to alternative fistula risk scoring system (A-FRS)
You will not qualify if you...
- Late-stage cancer with distant organ metastasis or extensive lymph node involvement
- Tumor invasion of major arteries or veins including superior mesenteric artery, celiac trunk, inferior vena cava, or abdominal aorta
- Congestive heart failure with NYHA class 3 or 4
- Uncontrolled hypertension
- Renal failure requiring dialysis
- Serious active infection greater than Grade 2
- Pregnancy or breastfeeding
- Major surgery within 4 weeks before starting the trial or not recovered from it
- Other malignant tumors unless cured for more than 3 years
- Recent upper gastrointestinal bleeding within 4 weeks or ongoing bleeding risk
- Poor compliance or unwillingness to sign informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongshan Hospital
Shanghai, Shanghai Municipality, China, 200000
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here